38,200 Shares in Amphastar Pharmaceuticals, Inc. $AMPH Purchased by SummerHaven Investment Management LLC

SummerHaven Investment Management LLC acquired a new position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 38,200 shares of the company’s stock, valued at approximately $1,018,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Qube Research & Technologies Ltd lifted its holdings in shares of Amphastar Pharmaceuticals by 81.3% during the 2nd quarter. Qube Research & Technologies Ltd now owns 469,492 shares of the company’s stock worth $10,780,000 after acquiring an additional 210,511 shares during the period. Rice Hall James & Associates LLC acquired a new position in Amphastar Pharmaceuticals during the third quarter valued at approximately $3,447,000. Balyasny Asset Management L.P. lifted its stake in Amphastar Pharmaceuticals by 64.2% during the second quarter. Balyasny Asset Management L.P. now owns 266,306 shares of the company’s stock worth $6,114,000 after purchasing an additional 104,168 shares during the last quarter. Bridgeway Capital Management LLC acquired a new stake in shares of Amphastar Pharmaceuticals in the 2nd quarter valued at $1,954,000. Finally, Arrowstreet Capital Limited Partnership acquired a new stake in shares of Amphastar Pharmaceuticals in the 2nd quarter valued at $1,865,000. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH stock opened at $26.25 on Wednesday. The firm has a market capitalization of $1.21 billion, a price-to-earnings ratio of 11.62, a PEG ratio of 4.71 and a beta of 0.89. The company has a current ratio of 3.12, a quick ratio of 2.21 and a debt-to-equity ratio of 0.78. The business’s 50-day moving average price is $26.69 and its 200-day moving average price is $26.16. Amphastar Pharmaceuticals, Inc. has a 12 month low of $20.39 and a 12 month high of $37.38.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Thursday, November 6th. The company reported $0.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.10. Amphastar Pharmaceuticals had a net margin of 15.43% and a return on equity of 19.70%. The business had revenue of $191.84 million during the quarter, compared to analyst estimates of $186.90 million. Equities research analysts forecast that Amphastar Pharmaceuticals, Inc. will post 3.49 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on AMPH. Weiss Ratings reissued a “hold (c-)” rating on shares of Amphastar Pharmaceuticals in a report on Monday, December 29th. Zacks Research downgraded Amphastar Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 14th. Barclays assumed coverage on shares of Amphastar Pharmaceuticals in a research note on Tuesday, December 9th. They issued an “equal weight” rating and a $30.00 price target on the stock. Finally, Needham & Company LLC decreased their price target on shares of Amphastar Pharmaceuticals from $36.00 to $34.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Two investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $31.00.

Insider Activity

In related news, Director Floyd F. Petersen sold 16,679 shares of the firm’s stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $26.49, for a total transaction of $441,826.71. Following the completion of the transaction, the director directly owned 75,531 shares of the company’s stock, valued at $2,000,816.19. This trade represents a 18.09% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Richard K. Prins sold 4,179 shares of Amphastar Pharmaceuticals stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $27.10, for a total value of $113,250.90. Following the transaction, the director directly owned 35,183 shares in the company, valued at $953,459.30. The trade was a 10.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 35,308 shares of company stock valued at $931,637. Insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.